Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

GOVX vs SIGA vs NVAX vs AGEN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GOVX
GeoVax Labs, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$2M
5Y Perf.-96.3%
SIGA
SIGA Technologies, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$339M
5Y Perf.-31.1%
NVAX
Novavax, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.50B
5Y Perf.-91.5%
AGEN
Agenus Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$132M
5Y Perf.-95.3%

GOVX vs SIGA vs NVAX vs AGEN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GOVX logoGOVX
SIGA logoSIGA
NVAX logoNVAX
AGEN logoAGEN
IndustryBiotechnologyDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnology
Market Cap$2M$339M$1.50B$132M
Revenue (TTM)$2M$94M$596M$114M
Net Income (TTM)$-21M$-4.04T$-88M$115K
Gross Margin100.0%61.8%84.6%35.7%
Operating Margin-8.7%27.7%-11.2%-17.7%
Forward P/E2.8x3.6x1.8x
Total Debt$843.17B$595K$249M$10M
Cash & Equiv.$6M$155M$241M$3M

GOVX vs SIGA vs NVAX vs AGENLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GOVX
SIGA
NVAX
AGEN
StockSep 20May 26Return
GeoVax Labs, Inc. (GOVX)1003.7-96.3%
SIGA Technologies, … (SIGA)10068.9-31.1%
Novavax, Inc. (NVAX)1008.5-91.5%
Agenus Inc. (AGEN)1004.7-95.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: GOVX vs SIGA vs NVAX vs AGEN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AGEN leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. SIGA Technologies, Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. GOVX and NVAX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
GOVX
GeoVax Labs, Inc.
The Momentum Pick

GOVX is the clearest fit if your priority is momentum.

  • +89.4% vs SIGA's +1.5%
Best for: momentum
SIGA
SIGA Technologies, Inc.
The Income Pick

SIGA is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 4 yrs, beta 1.15, yield 12.7%
  • 7.6% 10Y total return vs NVAX's -90.4%
  • Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
  • Beta 1.15, yield 12.7%, current ratio 11.83x
Best for: income & stability and long-term compounding
NVAX
Novavax, Inc.
The Growth Play

NVAX is the clearest fit if your priority is growth exposure.

  • Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
  • 64.7% revenue growth vs GOVX's -37.1%
Best for: growth exposure
AGEN
Agenus Inc.
The Value Play

AGEN carries the broadest edge in this set and is the clearest fit for value and quality.

  • Lower P/E (1.8x vs 3.6x)
  • 0.1% margin vs SIGA's -43K%
  • 0.1% ROA vs NVAX's -7.4%
Best for: value and quality
See the full category breakdown
CategoryWinnerWhy
GrowthNVAX logoNVAX64.7% revenue growth vs GOVX's -37.1%
ValueAGEN logoAGENLower P/E (1.8x vs 3.6x)
Quality / MarginsAGEN logoAGEN0.1% margin vs SIGA's -43K%
Stability / SafetySIGA logoSIGABeta 1.15 vs AGEN's 2.72
DividendsSIGA logoSIGA12.7% yield; 4-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)GOVX logoGOVX+89.4% vs SIGA's +1.5%
Efficiency (ROA)AGEN logoAGEN0.1% ROA vs NVAX's -7.4%

GOVX vs SIGA vs NVAX vs AGEN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GOVXGeoVax Labs, Inc.
FY 2022
NIH Grants
100.0%$81,526
SIGASIGA Technologies, Inc.
FY 2025
Product Sales and Supportive Services
93.1%$88M
Research and Development
6.9%$7M
NVAXNovavax, Inc.
FY 2025
Product
50.0%$685M
Nuvaxovid Sales
45.6%$625M
Supply Sales
4.4%$60M
AGENAgenus Inc.
FY 2025
Non Cash Royalty Revenue
99.1%$109M
Other
0.9%$1M

GOVX vs SIGA vs NVAX vs AGEN — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSIGALAGGINGAGEN

Income & Cash Flow (Last 12 Months)

Evenly matched — GOVX and SIGA and AGEN each lead in 2 of 6 comparable metrics.

NVAX is the larger business by revenue, generating $596M annually — 239.6x GOVX's $2M. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, AGEN holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGOVX logoGOVXGeoVax Labs, Inc.SIGA logoSIGASIGA Technologies…NVAX logoNVAXNovavax, Inc.AGEN logoAGENAgenus Inc.
RevenueTrailing 12 months$2M$94M$596M$114M
EBITDAEarnings before interest/tax-$22M$26M-$47M-$10M
Net IncomeAfter-tax profit-$21M-$4.04T-$88M$115,000
Free Cash FlowCash after capex-$21M$33M-$96M-$159M
Gross MarginGross profit ÷ Revenue+100.0%+61.8%+84.6%+35.7%
Operating MarginEBIT ÷ Revenue-8.7%+27.7%-11.2%-17.7%
Net MarginNet income ÷ Revenue-8.6%-43117.4%-14.7%+0.1%
FCF MarginFCF ÷ Revenue-8.6%+35.2%-16.1%-139.1%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%-11.3%-79.1%+27.5%
EPS Growth (YoY)Latest quarter vs prior year+86.9%-102.0%+85.3%
Evenly matched — GOVX and SIGA and AGEN each lead in 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — GOVX and AGEN each lead in 2 of 5 comparable metrics.

At 3.6x trailing earnings, NVAX trades at a 75% valuation discount to SIGA's 14.3x P/E. On an enterprise value basis, NVAX's 2.6x EV/EBITDA is more attractive than SIGA's 7.6x.

MetricGOVX logoGOVXGeoVax Labs, Inc.SIGA logoSIGASIGA Technologies…NVAX logoNVAXNovavax, Inc.AGEN logoAGENAgenus Inc.
Market CapShares × price$2M$339M$1.5B$132M
Enterprise ValueMkt cap + debt − cash$843.2B$185M$1.5B$140M
Trailing P/EPrice ÷ TTM EPS-0.08x14.33x3.63x-1102.94x
Forward P/EPrice ÷ next-FY EPS est.2.78x1.79x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.60x2.56x
Price / SalesMarket cap ÷ Revenue0.68x3.58x1.34x1.16x
Price / BookPrice ÷ Book value/share0.00x1.70x
Price / FCFMarket cap ÷ FCF6.96x
Evenly matched — GOVX and AGEN each lead in 2 of 5 comparable metrics.

Profitability & Efficiency

SIGA leads this category, winning 4 of 9 comparable metrics.

GOVX delivers a -0.0% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-11 for SIGA. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to GOVX's 0.22x. On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs GOVX's 4/9, reflecting solid financial health.

MetricGOVX logoGOVXGeoVax Labs, Inc.SIGA logoSIGASIGA Technologies…NVAX logoNVAXNovavax, Inc.AGEN logoAGENAgenus Inc.
ROE (TTM)Return on equity-0.0%-10.7%
ROA (TTM)Return on assets-0.0%-7.4%-7.4%+0.1%
ROICReturn on invested capital-0.0%+33.7%
ROCEReturn on capital employed-0.0%+11.3%+100.4%
Piotroski ScoreFundamental quality 0–94556
Debt / EquityFinancial leverage0.22x0.00x
Net DebtTotal debt minus cash$843.2B-$154M$8M$7M
Cash & Equiv.Liquid assets$6M$155M$241M$3M
Total DebtShort + long-term debt$843.2B$595,169$249M$10M
Interest CoverageEBIT ÷ Interest expense-5.10x1.11x
SIGA leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — GOVX and SIGA and NVAX each lead in 2 of 6 comparable metrics.

A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $197 for GOVX. Over the past 12 months, GOVX leads with a +89.4% total return vs SIGA's +1.5%. The 3-year compound annual growth rate (CAGR) favors NVAX at 7.4% vs AGEN's -51.0% — a key indicator of consistent wealth creation.

MetricGOVX logoGOVXGeoVax Labs, Inc.SIGA logoSIGASIGA Technologies…NVAX logoNVAXNovavax, Inc.AGEN logoAGENAgenus Inc.
YTD ReturnYear-to-date+750.2%-15.0%+29.5%+16.1%
1-Year ReturnPast 12 months+89.4%+1.5%+55.1%+27.1%
3-Year ReturnCumulative with dividends-82.4%+22.2%+23.9%-88.2%
5-Year ReturnCumulative with dividends-98.0%+1.4%-94.8%-93.9%
10-Year ReturnCumulative with dividends-96.0%+764.0%-90.4%-94.3%
CAGR (3Y)Annualised 3-year return-43.9%+6.9%+7.4%-51.0%
Evenly matched — GOVX and SIGA and NVAX each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SIGA and NVAX each lead in 1 of 2 comparable metrics.

SIGA is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVAX currently trades 77.1% from its 52-week high vs GOVX's 40.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGOVX logoGOVXGeoVax Labs, Inc.SIGA logoSIGASIGA Technologies…NVAX logoNVAXNovavax, Inc.AGEN logoAGENAgenus Inc.
Beta (5Y)Sensitivity to S&P 5002.23x1.15x2.11x2.72x
52-Week HighHighest price in past year$4.40$9.62$11.97$7.34
52-Week LowLowest price in past year$0.12$4.29$5.80$2.71
% of 52W HighCurrent price vs 52-week peak+40.0%+49.2%+77.1%+51.1%
RSI (14)Momentum oscillator 0–10067.847.064.448.8
Avg Volume (50D)Average daily shares traded217K688K4.4M814K
Evenly matched — SIGA and NVAX each lead in 1 of 2 comparable metrics.

Analyst Outlook

SIGA leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SIGA as "Buy", NVAX as "Buy", AGEN as "Buy". Consensus price targets imply 95.5% upside for AGEN (target: $7) vs 95.0% for NVAX (target: $18). SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.

MetricGOVX logoGOVXGeoVax Labs, Inc.SIGA logoSIGASIGA Technologies…NVAX logoNVAXNovavax, Inc.AGEN logoAGENAgenus Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$18.00$7.33
# AnalystsCovering analysts12311
Dividend YieldAnnual dividend ÷ price+12.7%
Dividend StreakConsecutive years of raises411
Dividend / ShareAnnual DPS$0.60
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.3%+0.1%
SIGA leads this category, winning 1 of 1 comparable metric.
Key Takeaway

SIGA leads in 2 of 6 categories — strongest in Profitability & Efficiency and Analyst Outlook. 4 categories are tied.

Best OverallSIGA Technologies, Inc. (SIGA)Leads 2 of 6 categories
Loading custom metrics...

GOVX vs SIGA vs NVAX vs AGEN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is GOVX or SIGA or NVAX or AGEN a better buy right now?

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -37. 1% for GeoVax Labs, Inc. (GOVX). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GOVX or SIGA or NVAX or AGEN?

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus SIGA Technologies, Inc. at 14. 3x. On forward P/E, Agenus Inc. is actually cheaper at 1. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — GOVX or SIGA or NVAX or AGEN?

Over the past 5 years, SIGA Technologies, Inc.

(SIGA) delivered a total return of +1. 4%, compared to -98. 0% for GeoVax Labs, Inc. (GOVX). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus GOVX's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GOVX or SIGA or NVAX or AGEN?

By beta (market sensitivity over 5 years), SIGA Technologies, Inc.

(SIGA) is the lower-risk stock at 1. 15β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 137% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 22% for GeoVax Labs, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — GOVX or SIGA or NVAX or AGEN?

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -37. 1% for GeoVax Labs, Inc. (GOVX). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, GOVX leads at 212. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GOVX or SIGA or NVAX or AGEN?

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -862. 3% for GeoVax Labs, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -869. 3% for GOVX. At the gross margin level — before operating expenses — GOVX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GOVX or SIGA or NVAX or AGEN more undervalued right now?

On forward earnings alone, Agenus Inc.

(AGEN) trades at 1. 8x forward P/E versus 2. 8x for SIGA Technologies, Inc. — 1. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.

08

Which pays a better dividend — GOVX or SIGA or NVAX or AGEN?

In this comparison, SIGA (12.

7% yield) pays a dividend. GOVX, NVAX, AGEN do not pay a meaningful dividend and should not be held primarily for income.

09

Is GOVX or SIGA or NVAX or AGEN better for a retirement portfolio?

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). GeoVax Labs, Inc. (GOVX) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, GOVX: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GOVX and SIGA and NVAX and AGEN?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GOVX is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; NVAX is a small-cap high-growth stock; AGEN is a small-cap quality compounder stock. SIGA pays a dividend while GOVX, NVAX, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

GOVX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 60%
Run This Screen
Stocks Like

SIGA

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 37%
  • Dividend Yield > 5.0%
Run This Screen
Stocks Like

NVAX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 50%
Run This Screen
Stocks Like

AGEN

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Gross Margin > 21%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GOVX and SIGA and NVAX and AGEN on the metrics below

Revenue Growth>
%
(GOVX: -100.0% · SIGA: -11.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.